• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关联突变特征执行过程与驱动基因和非编码区域突变热点。

Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions.

机构信息

Division of Molecular Genetics and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Computational Oncology Group, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) and DKFZ, Heidelberg, Germany.

出版信息

Nat Commun. 2022 Jan 10;13(1):178. doi: 10.1038/s41467-021-27792-6.

DOI:10.1038/s41467-021-27792-6
PMID:35013316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8748499/
Abstract

Cancer driving mutations are difficult to identify especially in the non-coding part of the genome. Here, we present sigDriver, an algorithm dedicated to call driver mutations. Using 3813 whole-genome sequenced tumors from International Cancer Genome Consortium, The Cancer Genome Atlas Program, and a childhood pan-cancer cohort, we employ mutational signatures based on single-base substitution in the context of tri- and penta-nucleotide motifs for hotspot discovery. Knowledge-based annotations on mutational hotspots reveal enrichment in coding regions and regulatory elements for 6 mutational signatures, including APOBEC and somatic hypermutation signatures. APOBEC activity is associated with 32 hotspots of which 11 are known and 11 are putative regulatory drivers. Somatic single nucleotide variants clusters detected at hypermutation-associated hotspots are distinct from translocation or gene amplifications. Patients carrying APOBEC induced PIK3CA driver mutations show lower occurrence of signature SBS39. In summary, sigDriver uncovers mutational processes associated with known and putative tumor drivers and hotspots particularly in the non-coding regions of the genome.

摘要

癌症驱动突变很难识别,尤其是在基因组的非编码部分。在这里,我们提出了 sigDriver,这是一种专门用于调用驱动突变的算法。我们使用了来自国际癌症基因组联盟、癌症基因组图谱计划和儿童泛癌队列的 3813 个全基因组测序肿瘤,基于三核苷酸和五核苷酸基序中单碱基替换的突变特征,用于热点发现。基于突变热点的知识注释显示,在编码区域和调控元件中,6 个突变特征(包括 APOBEC 和体细胞超突变特征)富集。APOBEC 活性与 32 个热点相关,其中 11 个是已知的,11 个是假定的调控驱动因素。在与超突变相关的热点检测到的体细胞单核苷酸变异簇与易位或基因扩增不同。携带 APOBEC 诱导的 PIK3CA 驱动突变的患者,特征 SBS39 的发生率较低。总之,sigDriver 揭示了与已知和假定的肿瘤驱动因素和热点相关的突变过程,特别是在基因组的非编码区域。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/666ec32db810/41467_2021_27792_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/8d1e07284b84/41467_2021_27792_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/30efd5805778/41467_2021_27792_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/ffb862713bf3/41467_2021_27792_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/841a73c69119/41467_2021_27792_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/666ec32db810/41467_2021_27792_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/8d1e07284b84/41467_2021_27792_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/30efd5805778/41467_2021_27792_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/ffb862713bf3/41467_2021_27792_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/841a73c69119/41467_2021_27792_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dadd/8748499/666ec32db810/41467_2021_27792_Fig5_HTML.jpg

相似文献

1
Association of mutation signature effectuating processes with mutation hotspots in driver genes and non-coding regions.关联突变特征执行过程与驱动基因和非编码区域突变热点。
Nat Commun. 2022 Jan 10;13(1):178. doi: 10.1038/s41467-021-27792-6.
2
Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.鉴定膀胱癌中 APOBEC 诱导热点突变中新的驱动和乘客突变。
Genome Med. 2020 Sep 28;12(1):85. doi: 10.1186/s13073-020-00781-y.
3
Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis. characterizes mutational signatures in human cancer cell lines reveals episodic aPOBEC mutagenesis
Cell. 2019 Mar 7;176(6):1282-1294.e20. doi: 10.1016/j.cell.2019.02.012.
4
Identification of coding and non-coding mutational hotspots in cancer genomes.癌症基因组中编码和非编码突变热点的鉴定。
BMC Genomics. 2017 Jan 5;18(1):17. doi: 10.1186/s12864-016-3420-9.
5
Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.对 7815 个癌症外显子组的分析揭示了突变过程与体细胞驱动突变之间的关联。
PLoS Genet. 2018 Nov 9;14(11):e1007779. doi: 10.1371/journal.pgen.1007779. eCollection 2018 Nov.
6
APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.APOBEC 突变驱动隐性营养不良性大疱性表皮松解症的早发性鳞状细胞癌。
Sci Transl Med. 2018 Aug 22;10(455). doi: 10.1126/scitranslmed.aas9668.
7
APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.载脂蛋白B mRNA编辑酶催化多肽样蛋白(APOBEC)特征性突变产生一种致癌增强子,该增强子驱动T细胞急性淋巴细胞白血病(T-ALL)中LMO1的表达。
Leukemia. 2017 Oct;31(10):2057-2064. doi: 10.1038/leu.2017.75. Epub 2017 Mar 6.
8
APOBEC and ADAR deaminases may cause many single nucleotide polymorphisms curated in the OMIM database.载脂蛋白B mRNA编辑酶催化多肽样蛋白(APOBEC)和腺苷脱氨酶(ADAR)可能导致在线孟德尔遗传数据库(OMIM)中整理的许多单核苷酸多态性。
Mutat Res. 2018 Jul;810:33-38. doi: 10.1016/j.mrfmmm.2018.03.008. Epub 2018 Jun 22.
9
Mechanisms of APOBEC3 mutagenesis in human cancer cells.APOBEC3 在人类癌细胞中致突变的机制。
Nature. 2022 Jul;607(7920):799-807. doi: 10.1038/s41586-022-04972-y. Epub 2022 Jul 20.
10
Mutational processes of tobacco smoking and APOBEC activity generate protein-truncating mutations in cancer genomes.吸烟和 APOBEC 活性的突变过程会在癌症基因组中产生蛋白截断突变。
Sci Adv. 2023 Nov 3;9(44):eadh3083. doi: 10.1126/sciadv.adh3083.

引用本文的文献

1
Genomic characterization of tumor mutational burden-high breast carcinomas.肿瘤突变负荷高的乳腺癌的基因组特征分析
NPJ Precis Oncol. 2025 Aug 8;9(1):277. doi: 10.1038/s41698-025-01045-x.
2
Identification and Validation of a Previously Missed Mutational Signature in Colorectal Cancer.结直肠癌中一种先前被遗漏的突变特征的鉴定与验证
bioRxiv. 2025 Jun 7:2025.06.06.658321. doi: 10.1101/2025.06.06.658321.
3
APOBEC affects tumor evolution and age at onset of lung cancer in smokers.载脂蛋白B mRNA编辑酶催化多肽样蛋白影响吸烟者肺癌的肿瘤演变和发病年龄。

本文引用的文献

1
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.CATCH:一项转移性乳腺癌的前瞻性精准肿瘤学试验。
JCO Precis Oncol. 2021 Apr 22;5. doi: 10.1200/PO.20.00248. eCollection 2021.
2
An extended APOBEC3A mutation signature in cancer.癌症中扩展的 APOBEC3A 突变特征。
Nat Commun. 2021 Mar 11;12(1):1602. doi: 10.1038/s41467-021-21891-0.
3
Analysis of mutational signatures with yet another package for signature analysis.使用另一个签名分析包分析突变特征。
Nat Commun. 2025 May 21;16(1):4711. doi: 10.1038/s41467-025-59923-8.
4
Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid.非肌层浸润性膀胱癌的基因组亚型:指导暴露于马兜铃酸的患者的免疫治疗决策
Mol Med. 2025 Apr 17;31(1):140. doi: 10.1186/s10020-025-01199-1.
5
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).大规模重复进化理论与癌症驱动核苷酸(CDN)的完全鉴定。
Elife. 2024 Dec 17;13:RP99340. doi: 10.7554/eLife.99340.
6
Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.在转移性尿路上皮癌中进行 APOBEC 诱变的全基因组图谱分析,确定了驱动热点突变和一个新的突变特征。
Cell Genom. 2024 Apr 10;4(4):100528. doi: 10.1016/j.xgen.2024.100528. Epub 2024 Mar 28.
7
The Crucial Findings Derived from the Special Issue "Inside Cancer Genomics: From Structure to Therapy".来自特刊《癌症基因组学内幕:从结构到治疗》的关键发现。
Cancers (Basel). 2023 Jul 4;15(13):3488. doi: 10.3390/cancers15133488.
8
Cancer driver mutations: predictions and reality.癌症驱动突变:预测与现实。
Trends Mol Med. 2023 Jul;29(7):554-566. doi: 10.1016/j.molmed.2023.03.007. Epub 2023 Apr 17.
9
Influence network model uncovers relations between biological processes and mutational signatures.影响网络模型揭示了生物过程与突变特征之间的关系。
Genome Med. 2023 Mar 6;15(1):15. doi: 10.1186/s13073-023-01162-x.
10
Cervical cancer heterogeneity: a constant battle against viruses and drugs.宫颈癌异质性:与病毒和药物的持续斗争。
Biomark Res. 2022 Nov 17;10(1):85. doi: 10.1186/s40364-022-00428-7.
Genes Chromosomes Cancer. 2021 May;60(5):314-331. doi: 10.1002/gcc.22918. Epub 2020 Dec 31.
4
PLEKHS1 Over-Expression is Associated with Metastases and Poor Outcomes in Papillary Thyroid Carcinoma.PLEKHS1过表达与甲状腺乳头状癌的转移及不良预后相关。
Cancers (Basel). 2020 Jul 31;12(8):2133. doi: 10.3390/cancers12082133.
5
A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies.一个用于突变特征分析的实用框架和在线工具显示了组织间的变异和驱动依赖性。
Nat Cancer. 2020 Feb;1(2):249-263. doi: 10.1038/s43018-020-0027-5. Epub 2020 Feb 17.
6
The repertoire of mutational signatures in human cancer.人类癌症中的突变特征谱。
Nature. 2020 Feb;578(7793):94-101. doi: 10.1038/s41586-020-1943-3. Epub 2020 Feb 5.
7
Analyses of non-coding somatic drivers in 2,658 cancer whole genomes.分析 2658 个癌症全基因组中的非编码体细胞驱动因子。
Nature. 2020 Feb;578(7793):102-111. doi: 10.1038/s41586-020-1965-x. Epub 2020 Feb 5.
8
Pan-cancer analysis of whole genomes.泛癌症全基因组分析。
Nature. 2020 Feb;578(7793):82-93. doi: 10.1038/s41586-020-1969-6. Epub 2020 Feb 5.
9
Combined burden and functional impact tests for cancer driver discovery using DriverPower.利用 DriverPower 进行癌症驱动基因发现的综合负担和功能影响测试。
Nat Commun. 2020 Feb 5;11(1):734. doi: 10.1038/s41467-019-13929-1.
10
Identification of cancer driver genes based on nucleotide context.基于核苷酸上下文识别癌症驱动基因。
Nat Genet. 2020 Feb;52(2):208-218. doi: 10.1038/s41588-019-0572-y. Epub 2020 Feb 3.